CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH). It is also known as Modified GRF 1-29 with DAC. This peptide is designed to stimulate the pituitary gland to release growth hormone (GH) in a pulsatile manner, mimicking the body's natural GH secretion pattern. The 'DAC' component significantly extends its half-life, allowing for less frequent administration compared to GHRH analogs without DAC. The primary interest in CJC-1295 with DAC centers on its potential to increase GH and insulin-like growth factor 1 (IGF-1) levels, which are associated with various physiological processes including muscle growth, fat reduction, and recovery. Its application is primarily in research and investigational contexts, with proponents citing potential benefits for body composition and regenerative processes. It is administered via subcutaneous injection.
CJC-1295 with DAC is not approved by regulatory bodies like the FDA for human use. Its use in humans is considered investigational and off-label, with limited clinical trial data available to support its efficacy and safety for specific medical conditions.
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
["PubChem", "DrugBank", "Journal of Clinical Endocrinology & Metabolism", "NIH Office of Dietary Supplements (general information on GH/IGF-1)"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the peptide category or studied for the same goals.